| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/25/2010 | CA2734687A1 Topical hydrogel composition |
| 02/25/2010 | CA2734678A1 New method for identifying compounds useful for treating and/or preventing disease-associated with bone loss |
| 02/25/2010 | CA2734655A1 Combinations comprising bicyclic s1p lyase inhibitors |
| 02/25/2010 | CA2734651A1 Methods for treating neuropathic pain |
| 02/25/2010 | CA2734650A1 Organoarsenic compounds and methods for the treatment of cancer |
| 02/25/2010 | CA2734585A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 02/25/2010 | CA2734491A1 Compositions and methods of using (r)-pramipexole |
| 02/25/2010 | CA2734489A1 Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | CA2734488A1 Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | CA2734487A1 Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | CA2734486A1 Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | CA2734459A1 Anthelmintic compositions |
| 02/25/2010 | CA2734398A1 7-azaindole derivatives |
| 02/25/2010 | CA2734397A1 Oxadiazole derivatives for the treatment of diabetes |
| 02/25/2010 | CA2734358A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/25/2010 | CA2734356A1 Improvements relating to nanodisperse compositions |
| 02/25/2010 | CA2734295A1 Processes for the preparation of sglt2 inhibitors |
| 02/25/2010 | CA2734168A1 3- and 6-quinolines with n-attached heterocyclic cgrp receptor antagonists |
| 02/25/2010 | CA2733790A1 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | CA2733688A1 New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
| 02/25/2010 | CA2733551A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 02/25/2010 | CA2733508A1 Compounds for the treatment of peripheral neuropathies |
| 02/25/2010 | CA2733359A1 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/25/2010 | CA2733250A1 Compounds as kinase inhibitors |
| 02/25/2010 | CA2732969A1 Novel compounds and their uses in diagnosis |
| 02/25/2010 | CA2731304A1 Methods for treating bleeding disorders |
| 02/25/2010 | CA2731068A1 Antiparasitic combinations comprising a 2-benzyl substituted imidazole and a 1-n-arylpyrazole |
| 02/25/2010 | CA2730478A1 Prodrugs of methyl hydrogen fumarate |
| 02/25/2010 | CA2730357A1 Azaindole inhibitors of iap |
| 02/25/2010 | CA2728103A1 Small molecule inhibitors of n-terminus activation of the androgen receptor |
| 02/24/2010 | EP2157097A1 Specific binding agents of human angiopoietin-2 |
| 02/24/2010 | EP2157095A2 Synthesis of beta-L-2-Deoxy nucleosides |
| 02/24/2010 | EP2157093A1 Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof |
| 02/24/2010 | EP2157091A1 Inhibitors of phosphatidylinositol 3-kinase |
| 02/24/2010 | EP2157090A1 Pyrazinamide compound |
| 02/24/2010 | EP2157089A1 The therapeutic uses of imidazol-5-carboxylic acid derivatives |
| 02/24/2010 | EP2157087A1 3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl)propyl]oxy}phenyl)-1-piperidinyl]carbonyl}-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders |
| 02/24/2010 | EP2157085A1 Oxazole, derivatives of tetracyclines |
| 02/24/2010 | EP2157084A1 5-phenyl-3-pyridazinone derivative |
| 02/24/2010 | EP2157083A2 Pharmaceutical compositions containing crystalline form (I) of lercanidipine hydrochloride |
| 02/24/2010 | EP2157082A1 Neurite formation promoter |
| 02/24/2010 | EP2157081A1 Indolinones substituted in six locations, their manufacture and their application as medicine |
| 02/24/2010 | EP2156863A2 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
| 02/24/2010 | EP2156862A1 Use of digitalis-like compounds in the treatment of affective disorders |
| 02/24/2010 | EP2156847A1 New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor. |
| 02/24/2010 | EP2156846A1 Prophylactic or therapeutic agent for diarrhea |
| 02/24/2010 | EP2156842A1 Oral composition |
| 02/24/2010 | EP2156840A2 Use of mometasone furoate for treating airway passage and lung diseases |
| 02/24/2010 | EP2156839A1 Method of treating movement disorders using barbituric acid derivatives |
| 02/24/2010 | EP2156838A1 Method for producing pharmaceutical tablet |
| 02/24/2010 | EP2156837A1 Crystalline micropowder particles |
| 02/24/2010 | EP2156836A1 SYNERGIC PHARMACEUTICAL COMPOSITIONS CONSISTING OF A COMBINATION OF A 5 alpha-REDUCTASE ENZYME INHIBITOR AND A 1 alpha- ADRENERGIC RECEPTOR ANTAGONIST |
| 02/24/2010 | EP2156835A1 New therapeutic use of drotaverine |
| 02/24/2010 | EP2156834A1 Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| 02/24/2010 | EP2156833A1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| 02/24/2010 | EP2156832A1 Pharmaceutical composition |
| 02/24/2010 | EP2156831A1 Augmented Cognitive Training |
| 02/24/2010 | EP2156830A1 Modulators of asparaginyl hydoxylase activity of FIH |
| 02/24/2010 | EP2156828A1 Method and dosage regimens for eliminating a chemical substance in blood |
| 02/24/2010 | EP2156826A1 Microcapsule formulations comprising two pharmaceutically active ingredients |
| 02/24/2010 | EP2156825A1 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses |
| 02/24/2010 | EP2156824A1 Composition of solifenacin or salt thereof for use in solid formulation |
| 02/24/2010 | EP2156823A1 Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles |
| 02/24/2010 | EP2156751A1 Novel sweetener having sugar-like taste and production method and use of the same |
| 02/24/2010 | EP2156189A1 Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins |
| 02/24/2010 | EP2155877A2 Rna antagonist compounds for the modulation of her3 |
| 02/24/2010 | EP2155776A2 Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof |
| 02/24/2010 | EP2155771A1 Azido purine nucleosides for treatment of viral infections |
| 02/24/2010 | EP2155758A1 Tetrahydrofuro ý3 4-d¨dioxolane compounds for use in the treatment of viral infections and cancer |
| 02/24/2010 | EP2155755A1 Compositions comprising c-13 alkoxyether macrolide compounds and phenylpyrazole compounds |
| 02/24/2010 | EP2155753A1 Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| 02/24/2010 | EP2155749A1 Pyrrolopyridine derivatives and their use as bace inhibitors |
| 02/24/2010 | EP2155748A1 Urotensin ii receptor antagonists |
| 02/24/2010 | EP2155747A1 Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| 02/24/2010 | EP2155746A2 Diazaquinolones that inhibit prolyl hydroxylase activity |
| 02/24/2010 | EP2155745A1 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives |
| 02/24/2010 | EP2155744A1 Heteroaryl amide analogues as p2x7 antagonists |
| 02/24/2010 | EP2155743A1 Imidazoquinolines with immuno-modulating properties |
| 02/24/2010 | EP2155742A1 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer |
| 02/24/2010 | EP2155740A1 Hetarylanilines as modulators for amyloid beta |
| 02/24/2010 | EP2155737A1 Gamma secretase modulators |
| 02/24/2010 | EP2155736A1 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| 02/24/2010 | EP2155735A2 Triazolyl aminopyrimidine compounds |
| 02/24/2010 | EP2155734A2 Triazolyl aminopyrimidine compounds |
| 02/24/2010 | EP2155733A1 Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
| 02/24/2010 | EP2155732A1 Amorphous olmesartan medoxomil |
| 02/24/2010 | EP2155731A1 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase |
| 02/24/2010 | EP2155730A2 Aminopyrimidines useful as kinase inhibitors |
| 02/24/2010 | EP2155729A1 Prolinamide-tetrazole derivatives as nk3 receptor antagonists |
| 02/24/2010 | EP2155728A2 Heterocyclic indazole derivatives |
| 02/24/2010 | EP2155727A1 N-[6-amino-5-(phenyl)pyrazin-2-yl]-isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| 02/24/2010 | EP2155726A1 Phthalazinone derivatives and their use as medicament to treat cancer |
| 02/24/2010 | EP2155723A2 New solid forms of fxa inhibitors |
| 02/24/2010 | EP2155722A1 Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| 02/24/2010 | EP2155721A1 Organic compounds |
| 02/24/2010 | EP2155720A1 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| 02/24/2010 | EP2155719A1 Azacyclylbenzamide derivatives as histamine-3 antagonists |
| 02/24/2010 | EP2155718A2 Aryloxazole, aryloxadiazole and benzimidazole derivatives as modulators of somatostatine receptor activity |
| 02/24/2010 | EP2155717A1 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists |
| 02/24/2010 | EP2155716A2 Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials |